Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-136109

Published: 2020

Journal Articles

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142871

Published: 2020

Journal Articles

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Laurie H. Sehn, MDMPH, Mark Hertzberg, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Alex F. Herrera, MD, Sarit E Assouline, MD MSc, Christopher Flowers, MDMS, Tae Min Kim, MD PhD, Andrew McMillan, Muhit Ozcan, Violaine Safar, Gilles Salles, MD PhD, Lisa Musick, Jamie Hirata, YiMeng Chang, Grace Ku, Matthew J Matasar, MD

Blood (2020) 136 (Supplement 1): 17–19.

https://doi.org/10.1182/blood-2020-137078

Published: 2020

Journal Articles

Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis

Eliane Nguyen, MD, Natasha Szuber, MD, Michael Harnois, Lambert Busque, MD, Luigina Mollica, MD FRCPC, PhD, Sarit E Assouline, MD MSc, Ines Chamakhi, MD MD FRCP(C), Harold J. Olney, MD, Shireen Sirhan, MD

Blood (2020) 136 (Supplement 1): 4–7.

https://doi.org/10.1182/blood-2020-141835

Published: 2020

Journal Articles

Retro-Prospective Observational Study on the Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO)

Carlo Gambacorti-Passerini, MD, Alberto Alvarez-Larrán, MD, Sarit E Assouline, MD MSc, Patrizia Pregno, Philipp D le Coutre, MD, Susanne Saussele, MD, Laura Antolini, PhD, Brian J. Druker, MD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-140234

Published: 2020

Journal Articles

Single-Cell Transcriptomic Profiling of De Novo and Relapsed Acute Myeloid Leukemia Identifies a Leukemic Stemness Program Shared across Diverse Phenotypes

Samantha Worme, BSc, Selin Jessa, BSc, William Poon, BSc, Maja Jankovic, MSc, Gabriela Galicia Vazquez, PhD, Alexandre Bazinet, MD, Katharine Fooks, BSc, Isabella Iasenza, BSc, Patricia Arreba-Tutusaus, PhD, Kolja Eppert, PhD, Ioannis Ragoussis, PhD, Yu Chang Wang, PhD, Nathalie A Johnson, MD PhD, Sarit E Assouline, MD MSc, Claudia L Kleinman, PhD, François E Mercier, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143221

Published: 2020

Journal Articles

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Claire Andrews, Taylor Young, Eshetu G Atenafu, M.Sc., P.Stat, Sarit E Assouline, MD MSc, Joseph M Brandwein, MD, Steven M Chan, MD PhD, Signy Chow, MD FRCP(C), Dina Khalaf, BSc, MSc, MD, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MD, Dawn Maze, MDFRCPC,MSc, Mark D. Minden, Caroline J McNamara, MBBS, Tracy Murphy, MDFRCP,FRCPath, David Sanford, MD, Aaron D Schimmer, MD PhD, Andre C. Schuh, Karen W.L. Yee, MD, Hassan Sibai, MBBS

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142990

Published: 2020

Journal Articles

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-135818

Published: 2020

Journal Articles

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-137245

Published: 2020

Journal Articles

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Francisco J. Hernandez-Ilizaliturri, MD, Ian W. Flinn, MD PhD, John Kuruvilla, MD, Sarit E Assouline, MD MSc, Matthew L. Ulrickson, MD, Beth A. Christian, MD, Daniel J. Landsburg, MD, Monic Stuart, MD MPH, Henry Lowman, PhD, Nancy Levin, PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-142859

Published: 2020

Journal Articles

Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-135839

Published: 2020

Journal Articles

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma

Blood (2016) 128 (22): 1218.

https://doi.org/10.1182/blood.V128.22.1218.1218

Published: 2016

Journal Articles

Safe and Effective Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat

Kerry J. Savage, MD MSc, Steven M. Horwitz, MD, Pier Luigi Zinzani, MD, PhD, Achiel Van Hoof, Sarit E. Assouline, MD, Gajanan Bhat, Mi Rim Choi, Lee F Allen, Dina Ben-Yehuda, MD, Wojciech Jurczak, Tamas Masszi, MD, Andrei R. Shustov, MD

Blood (2014) 124 (21): 3075.

https://doi.org/10.1182/blood.V124.21.3075.3075

Published: 2014

Journal Articles

Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Maria Corinna Palanca-Wessels, M.D., Ph.D., Gilles Andre Salles, MD, PhD, Myron S. Czuczman, MD, Sarit E. Assouline, MD, Ian W. Flinn, MD, PhD, Laurie H. Sehn, MD, Manish Patel, MD, Randeep Sangha, Herve Tilly, MD, Ranjana Advani, MD, Olivier Casasnovas, MD, Oliver W. Press, MD, PhD, Sreeni Yalamanchili, BSPharm, Robert Kahn, Dan Lu, Akiko Chai, MS, Yu-Waye Chu, Franck Morschhauser

Blood (2013) 122 (21): 4400.

https://doi.org/10.1182/blood.V122.21.4400.4400

Published: 2013

Journal Articles

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Maria Corinna Palanca-Wessels, M.D., Ph.D., Ian W. Flinn, MD, PhD, Laurie H. Sehn, MD, MPH, Manish Patel, MD, Randeep Sangha, MD, Myron S. Czuczman, MD, Gilles Andre Salles, MD, PhD, Franck Morschhauser, MD, Ranjana Advani, MD, Oliver W. Press, MD, PhD, William Ho, MD, PhD, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, Sarit E. Assouline, MD

Blood (2012) 120 (21): 56.

https://doi.org/10.1182/blood.V120.21.56.56

Published: 2012

Journal Articles

Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592)

Arnold S. Freedman, MD, John Kuruvilla, MD, Sarit E. Assouline, MD, Andreas Engert, MD, DaeSeog Heo, MD, Philippe Solal-Celigny, MD, Paolo Corradini, MD, Gregor Verhoef, MD, PhD, Michelle A. Fanale, MD, Jennifer Bendiske, PhD, Brett Ewald, PhD, Jyotirmoy Dey, PhD, Johan Baeck, MD, Anas Younes, MD

Blood (2010) 116 (21): 284.

https://doi.org/10.1182/blood.V116.21.284.284

Published: 2010

Journal Articles

Diffuse Large B-Cell Lymphoma in the Very Elderly, a Study of Outcome in Patients Aged 80 and Older.

Cindy Varga, MD, BSC, Sarit E. Assouline, MD

Blood (2009) 114 (22): 1942.

https://doi.org/10.1182/blood.V114.22.1942.1942

Published: 2009

Journal Articles

Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib.

Michael Deininger, MD, PhD, François-Xavier Mahon, MD, Francois Guilhot, MD, Giuseppe Saglio, MD, Philipp le Coutre, MD, Arnon Nagler, MD, Anna D'Emilio, MD, Fabio Stagno, Enrica Morra, MD, Andrea Piccin, MD, Sarit E. Assouline, MD, Elisabetta Abruzzese, Valeria Santini, MD, Fabrizio Pane, MD, Pilar Giraldo, MD, Laura Antolini, PhD, Maria Grazia Valsecchi, PhD, Carlo Gambacorti-Passerini, MD

Blood (2009) 114 (22): 1108.

https://doi.org/10.1182/blood.V114.22.1108.1108

Published: 2009

Journal Articles

Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic Avenue in Acute Myeloid Leukemia.

Sarit E. Assouline, MD, Eftihia Cocolakis, PhD, Caroline Rousseau, PhD, Biljana Culjkovic, PhD, Nathalie Beslu, PhD, Abdellatif Amri, Stephen N. Caplan, MD, Brian Leber, MD, Denis-Claude Roy, MD, Katherine L. B. Borden, PhD, Wilson H. Miller, Jr., MD, PhD

Blood (2009) 114 (22): 2085.

https://doi.org/10.1182/blood.V114.22.2085.2085

Published: 2009

Journal Articles

A Phase I Study of GA101 (RO5072759) Monotherapy Followed by Maintenance in Patients with Multiply Relapsed/Refractory CD20 + Malignant Disease.

Laurie H. Sehn, MD, MPH, Sarit E. Assouline, MD, Douglas A. Stewart, MD, Joy Mangel, MD, FRCPC, Pavel Pisa, MD, PhD, Jaimal Kothari, MD, Michael Crump, MD

Blood (2009) 114 (22): 934.

https://doi.org/10.1182/blood.V114.22.934.934

Published: 2009

NARROW

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis

Retro-Prospective Observational Study on the Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO)

Single-Cell Transcriptomic Profiling of De Novo and Relapsed Acute Myeloid Leukemia Identifies a Leukemic Stemness Program Shared across Diverse Phenotypes

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma

Safe and Effective Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat

Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592)

Diffuse Large B-Cell Lymphoma in the Very Elderly, a Study of Outcome in Patients Aged 80 and Older.

Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib.

Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic Avenue in Acute Myeloid Leukemia.

A Phase I Study of GA101 (RO5072759) Monotherapy Followed by Maintenance in Patients with Multiply Relapsed/Refractory CD20 + Malignant Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only